Clinical Trial

CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Name: CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies — clinical trial record (NCT07763938)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

Phase Ib Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product in the Treatment of Relapsed/Refractory B-cell Malignancies

Trial Details

NCT Number	NCT07763938
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University Collaborators: Nanjing Legend Biotech Co.
Conditions	Relapsed/Refractory B-cell Malignancies
Enrollment	80 participants
Start Date	2026-11-01
Primary Completion	2029-12-30 (estimated)
Study Completion	2032-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-13